The strong EPS beat and robust lymphedema growth are positive, but the guidance trim due to airway clearance destocking introduces uncertainty. Monitor next quarter's DME ordering patterns and the ramp of the next-gen AffloVest system for confirmation that destocking is temporary.
Price Chart
Executive Summary
Tactile Systems Technology reported Q2 2026 total revenue of $85.7M (up 9% YoY, roughly in line with consensus), but EPS of $0.34 significantly beat the $0.17 consensus estimate. However, the company narrowed its full-year revenue guidance to $360M-$366M from $360M-$368M due to temporary inventory destocking at DME providers for the AffloVest system, partially offsetting the strong quarter.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $85.7M, up 9% YoY from $78.9M
- GAAP diluted EPS $0.34 vs $0.14 in Q2 2025, beating consensus of $0.17
- Net income $7.8M vs $3.2M in Q2 2025
- Gross margin expanded to 76% from 75% YoY
- Full-year 2026 revenue guidance narrowed to $360M-$366M (from $360M-$368M), reflecting 9-11% YoY growth
- Adjusted EBITDA $11.4M vs $7.7M in Q2 2025
- Operating cash flow $2.9M for first half 2026 vs $15.2M in prior year period
- Airway clearance product line sales fell 7% YoY due to inventory destocking at large DME providers
- Company repurchased $5.3M of stock in Q2, with $18.7M remaining under $25M buyback program
- Entered exclusive U.S. distribution agreement with ElastiMed for MyoSleeve device to VA/DoD
- Cash balance $69.9M, no debt outstanding
Financial Impact
EPS surprise of +100% vs consensus ($0.34 actual vs $0.17 est) is large, but revenue surprise was modest (~$85.7M vs $85.5M). The guidance trim is small ($2M at midpoint) but signals temporary headwinds in airway clearance.
Risk Factors
- DME destocking in airway clearance segment could persist longer than anticipated
- Share buyback reduces float but does not offset underlying business weakness in one segment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342201 |
Track record
17 reports on TCMD
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.99 Now $26.37 −2.30% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $27.11 Now $26.37 −2.73% settles Feb 12
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $26.62 Now $26.37 −0.94% settles Feb 8
- Nov 6, 202610d ago 3 Neutral 2/10 Entry $26.59 Now $26.37 −0.83% settles Feb 5
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago 10-Q/A Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago 10-Q/A Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Nov 2, 202614d ago Press Release Bearish 5/10 No price data
- Nov 2, 202614d ago 8-K Mixed 5/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
- Oct 19, 202628d ago Press Release Neutral 3/10 Entry $23.52 Now $26.37 +12.12% settles Jan 15
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers